

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number
WO 01/44444 A2

(51) International Patent Classification⁷: C12N 9/00

Yutaka [JP/JP]; Tsukuba Research Laboratories, Glaxo Wellcome Kabushiki Kaisha, 43, Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP).

(21) International Application Number: PCT/JP00/08873

(22) International Filing Date:
14 December 2000 (14.12.2000)

(74) Agents: SUZUYE, Takehiko et al.; Suzuye & Suzuye, 7-2, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo 100-0013 (JP).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9929542.0 14 December 1999 (14.12.1999) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): **GLAXO WELLCOME KABUSHIKI KAISHA** [JP/JP]; Shinjuku Maynds Tower, 1-1, Yoyogi 2-chome, Shibuya-ku, Tokyo 151-8566 (JP).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HASHIMOTO, Yasuhiro** [JP/JP]; Tsukuba Research Laboratories, Glaxo Wellcome Kabushiki Kaisha, 43, Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP). **TAKEMOTO, Yoshihiro** [JP/JP]; Tsukuba Research Laboratories, Glaxo Wellcome Kabushiki Kaisha, 43, Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP). **FURUTA, Masaaki** [JP/JP]; Tsukuba Research Laboratories, Glaxo Wellcome Kabushiki Kaisha, 43, Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP). **SAKAI,**

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IKK4

(57) Abstract: A novel inhibitory kappa B kinase (IKK) is disclosed herein as IKK4. Polynucleotides encoding IKK4, expression vectors comprising said polynucleotides and screening methods for identifying therapeutic modulators of IKK4 activity are also disclosed.



WO 01/44444 A2

I

DESCRIPTION

IKK4

This invention relates to a novel IKK kinase protein, IKK4, nucleotides encoding for it, vectors and host cells containing the same and methods for screening for modulators of said IKK4 protein for treatment of conditions involving inflammation.

The transcription factor NF- κ B controls the activation of various genes in response to pathogens and pro-inflammatory cytokines. Thus, for example, NF- κ B is activated by various kinds of stimulation including tumour necrosis factor alfa (TNF alfa) and interleukin -1 (IL-1), bacterial LPS, viral infection, antigen receptor cross-linking of T and B cells, calcium ionophores, phorbol esters, UV radiation and free radicals (for reviews, see Varma et al., 1995, Genes Dev., 9, 2723-2735; Baueürerle and Baltimore, 1996, Cell, 87, 13-20), (see Figure 1). NF- κ B in turn controls the activation of various genes in response to these stimuli. Activation of these various genes in turn may result in the production of cytokines, chemokines, leukocyte adhesion molecules, hematopoietic growth factors and may also effect development and cell death as well as cell survival (see Figure 1). Specifically, the transcription factor NF- κ B controls the activation of various genes in response to pathogens and pro-inflammatory cytokines. The NF- κ B activity is regulated through interaction with specific inhibitors, I κ Bs. Upon cell stimulation, the I κ Bs are rapidly phosphorylated and then undergo ubiquitin-mediated proteolysis, resulting in the release of active NF- κ B (Baldwin, 1996, Annu. Rev. Immunol., 14, 649-681; Baueürerle and Baltimore, 1996, Cell, 87, 13-20), (see Figure 2). It has been reported that the 700 kDa complex specifically phosphorylated I κ B α at S32 and S36 (Chen et al., 1996, Cell, 84, 853-862).

Several groups found that two kinases termed IKK1 (IKK α) and IKK2 (IKK β), were the subunits of the kinase complex. These groups showed that the IKK immunoprecipitates, derived from the TNF α or IL-1 stimulated cells which are able to phosphorylate I κ B in vitro. In addition to these observations, two groups reported that IKK1 and IKK2 purified from insect cells were able to phosphorylate I κ B in vitro. These results suggested that IKK directly phosphorylates I κ Bs. The over expression of anti-sense IKK1, kinase-inactive

IKK1 or IKK2 resulted in the inhibition of NF- κ B activation mediated by TNF α and IL-1. These results suggest that IKKs are critical kinases in the NF- κ B activation pathway (May and Ghosh, 1998, Immunol. Today 19, 80-88; Stancovski and Baltimore, 1997, Cell, 91, 299-302). It has, however, not been
5 understood how upstream signals are transmitted to the kinase complex, or whether different kinase complexes might exist to phosphorylate distinct I κ Bs.

NEMO (NF- κ B essential modifier) and IKK γ (human homologue of the mouse NEMO) were isolated from purified IKK complex, and the inhibition of
10 NEMO/IKK γ gene expression impaired the cytokine induced NF- κ B activation via IKK1 and IKK2. In NEMO deficient cells, smaller complexes of Mr 3,000-4,000 are formed, though the normal complex is Mr 7,000-9,000, suggesting that NEMO/IKK γ physically link I κ B kinase to upstream activators (Scheidereit, Nature, 1998, 395, 225-226).

15 The IKK-complex-associated protein (IKAP) was isolated from the IKK complexes. IKAP binds to I κ B kinases and NIK and the complex, containing three kinases, leads to the maximum phosphorylation of I κ B as compared to the complex containing one or two kinases. Accordingly, IKAP may act as scaffold
20 proteins that link NIK or other molecules to IKK1 and IKK2 (Scheidereit, Nature, 1998, 395, 225-226). Accumulating evidence suggests that the IKK complex consists of several essential molecules, however, the molecular mechanisms that control the signalling complex were not well understood. Therefore, further association molecules were needed to complete the picture.

25 KIAA0151 was originally isolated from the KG-1 cDNA library (Nagase et al., 1995, DNA Res, 2, 167-174). KIAA0151 was identified as a potential Ser/Thr kinase, however, the importance of the molecule was not recognised. We have now found that KIAA0151 is similar to IKK1 and IKK2 using a computer
30 homology analysis. KIAA0151, renamed IKK3, has a 21% homology with IKK1 and 23% with IKK2. IKK3 was able to phosphorylate I κ B family proteins and directly phosphorylate I κ B in vitro. The over expression of IKK3 leads to the activation of various inflammatory genes, such as IL-8, IL-6 and RANTES. These genes contain the NF- κ B site in the gene regulation region. We know that IKK3
35 has an effect on IL-8 expression in Hela cells and also that IKK3 phosphorylates

NF- κ B. Moreover, it is known that the NF- κ B site has an important role in IL-8 regulation. Our results suggest a correlation between IKK3 and the NF- κ B site of the IL-8 promoter that has previously been identified as an endogenous NF- κ B binding site, further suggesting that IKK3 plays an important role in controlling the NF- κ B site of the IL-8 promoter. These results lead to the conclusion that IKK3 is an important regulator of IL-8 gene regulation and thus activates genes that are important for the inflammatory diseases (see Table 1 below).

Table 1

Differences between IKK1, 2 and IKK3

	IKK ϵ , β (also known as IKK1 & IKK2)	IKK3
Expression (mRNA)	Constitutive	Inducible by IL-1 and TNF- α
Source for in vitro phosphorylation	Mammalian and Insect cells	Mammalian and Bacterial cells
Spectrum	Unknown	IL-8, IL-6 and RANTES
Substrate Selectively	I κ B α > I κ B β	I κ B ϵ I κ B β > I κ B α
Enzymatic activity	Need for IL-1 or TNF α stimulation	No need for stimulation

Using a computer homology analysis we have now we identified a novel kinase, termed IKK4, that is 49% similarity with IKK3, 25% identical to IKK1 and 24% identical to IKK2, at the amino acid level. The overexpression of IKK4 leads to the activation of the IL-8 reporter gene via NF- κ B signalling pathway. We found that IKK4 is able to phosphorylate I κ B family proteins using immunoprecipitation assays, and directly phosphorylate I κ B β in vitro using a GST-pull down assay. These results suggest that IKK4 activates the IL-8 gene as well as some other inflammatory related gene.

Accordingly this invention provides a novel isolated kinase protein, referred to herein as IKK4.

Nucleotide sequence of IKK4 reveals a 2187 bp open reading frame which encodes a 729 amino acid protein (see SEQ.I.D.NO:1). At the amino acid level, IKK4 is 49 % identical to IKK3, and 25% identical to IKK1 and 24% identical to IKK2. On the other hand, IKK1 has a 52% identity to IKK2. The amino acid
5 sequence of IKK4 revealed that it has a potential kinase domain, though IKK3 has two leucine zippers, and IKK1/IKK2 have one leucine zipper as reported previously. IKK1 and IKK2 have an HLH domain at the C-terminal region, however, we are unable to find a typical HLH domain, which were found in IKK1 and IKK2 (Figs. 3 and 4). The kinase domain of IKK3 and IKK4 have 73%
10 identity at the amino acid level. In addition, two domains in IKK3 and IKK4 were found similarity in the amino acid level. We termed these regions as HR1 and HR2. The IKK4 HR1 region (amino acids 300-450) and IKK3 HR1 region (amino acids, 300-450) are 43% identical at the amino acid level. The IKK4 HR2 region (amino acids, 562-609) and IKK3 HR2 region (amino acids, 552-600) are 50%
15 identical at the amino acid level.

One aspect of the invention therefore provides an isolated IKK4 kinase protein or a variant thereof. The amino acid sequence of this isolated IKK4 kinase protein is shown in SEQ I.D.No: 1.

20 By the term "isolated" we mean that the protein herein exists in a physical milieu distinct from that in which it occurs in nature. For example, the protein maybe substantially isolated with respect to the complex cellular milieu with which it is normally associated with. The absolute level of purity is not critical and maybe readily determined by the skilled person according to the use to which the
25 protein is put.

Included within the invention are variants of the IKK4 kinase protein. Such variants include fragments, analogues, derivatives and splice variants. The term "variant" refers to a protein or part of a protein which retains substantially the same biological function or activity as IKK4.

30 Fragments can include a part of IKK4 which retains sufficient identity of the original protein to be effective for example in a screen. Such fragments may be probes such as the ones described hereinafter for the identification of the full length protein. Fragments may be fused to other amino acids or proteins or may
35 be comprised within a larger protein. Such a fragment may be comprised within

a precursor protein designed for expression in a host. Therefore, in one aspect the term fragment means a portion or portions of a fusion protein or polypeptide derived from IKK4.

5 Fragments also include portions of IKK4 characterised by structural or functional attributes of the protein. These may have similar or improved chemical or biological activity or reduced side-effect activity. For example, fragments may comprise an alpha, alpha-helix or alpha-helix-forming region, beta sheet and beta-sheet-forming region, turn and turn-forming regions, coil and coil-forming
10 regions, hydrophilic regions, hydrophobic regions, amphipathic regions (alpha or beta), flexible regions, surface-forming regions, substrate binding regions and regions of high antigenic index.

15 Fragments or portions may be used for producing the corresponding full length protein by peptide synthesis.

Derivatives include naturally occurring allelic variants. An allelic variant is an alternate form of a protein sequence which may have a substitution, deletion or insertion of one or more amino acids, which does not substantially alter the
20 function of the protein. Derivatives can also be non-naturally occurring proteins or fragments in which a number of amino acids have been substituted, deleted, added, rearranged or modified. Proteins or fragments which have at least 70% identity to IKK4 are encompassed within the invention. Preferably, the identity is at least 80%, more preferably at least 90% and still more preferably at least or
25 greater than 95% identity for example 97%, 98% or even 99% identity to IKK4.

Analogues include but are not limited to precursor proteins which can be activated by cleavage of the precursor portion to produce an active mature protein or a fusion with a compound such as polyethylene glycol or a
30 leader/secretary to aid purification.

A splice variant is a protein product of the same gene, generated by alternative splicing of mRNA, that contains additions or deletions within the coding region (Lewin N (1995) Genes V Oxford University Press, Oxford, England). The

present invention covers splice variants of the IKK4 kinase protein that occur naturally and which may play a role in the control of inflammation.

5 The protein or variant of the present invention may be a recombinant protein, a natural protein or a synthetic protein, preferably a recombinant protein.

10 A further aspect of the invention provides an isolated (as defined *supra*) nucleotide sequence which encodes a mammalian IKK4 protein as described above, or a variant thereof. Also included within the invention are anti-sense nucleotides or complementary strands.

15 Preferably, the nucleotide sequence encodes the rat, murine or human IKK4 protein. The nucleotide sequence preferably comprises the sequence of the coding portion of the nucleotide sequence shown in SEQ I.D NO: 2.

A nucleotide sequence encoding an IKK4 protein of the present invention may be obtained from a cDNA or a genomic library derived from the human fetus Marathon-Ready cDNA (Clontech).

20 The nucleotide sequence may be isolated from a mammalian cell (preferably a human cell), by screening with a probe derived from the rat, murine or human IKK4 sequence, or by other methodologies known in the art such as preliminary chain reaction (PCR) for example on genomic DNA with appropriate oligonucleotide primers derived from or designed based on the rat, murine or
25 human IKK4 sequence and/or relatively conserved regions of known IKK3 proteins. A bacterial artificial chromosome library can be generated using rat or human DNA for the purposes of screening.

30 The nucleotide sequence of the present invention may be in form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single-stranded may be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the IKK4 protein or variant thereof may be identical to the coding sequence set forth in SEQ.I.D. NO:2, or maybe a different coding

sequence which as a result of the redundancy or degeneracy of the genetic code, encodes the same protein as the sequences set forth therein.

A nucleotide sequence which encodes an IKK protein may include:

5

a coding sequence for the full length protein or any variant thereof, and additional coding sequence such as a leader or secretory sequence or a pro-protein sequence: a coding sequence for the full length protein or any variant thereof (and optionally additional coding sequence) and non-coding sequences, such as introns or non-coding sequences 5' and/or 3' of the coding sequence for the full length protein. The invention also provides nucleotide variants, analogues, derivatives and fragments which encode IKK4. Nucleotides are included which preferably have at least 70% identity over the entire length to IKK4. More preferred are those sequences which have at least 80% identity over their entire length to IKK4. Even more preferred are polynucleotides which demonstrate at least 90% for example 95%, 97%, 98% or 99% identity over their entire length to IKK4

15

20

25

The present invention also relates to nucleotide probes constructed from the nucleotide sequence of an IKK protein or variant thereof. Such probes could be utilised to screen a cDNA or genomic library to isolate a nucleotide sequence encoding an IKK4 protein. The nucleotide probes can include portions of the nucleotide sequence of the IKK4 protein or variant thereof useful for hybridising with mRNA or DNA in assays to detect expression of the IKK4 protein or localised its presence on a chromosome using for example fluorescence in situ hybridisation (FISH).

30

The nucleotide sequences of the invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the protein of the present invention such as hexa-histidine tag or hemagglutinin (HA) tag, Myc-tag, T7-tag, double MYC-tag, double HA-tag and double T7-tag expression vectors or allows determination in screening assays of effective blockage of IKK4 or it's modulation.

Nucleotide molecules which hybridise to IKK4 or to complementary nucleotides thereto also form part of the invention. Hybridisation is preferably under stringent hybridisation conditions. One example of stringent hybridisation conditions which is sometimes used is where attempted hybridisation is carried out at a temperature of from about 35°C to about 65°C using a salt solution which is about 0.9 mol. However, the skilled person will be able to vary such conditions as appropriate in order to take into account variables such as probe length, base composition, type of ions present etc. The nucleotide sequence of the present invention may be employed for producing the IKK4 protein or variant thereof by recombinant techniques. Thus, for example the nucleotide sequence may be included in any one of a variety of expression vehicles or cloning vehicles, in particular vectors or plasmids for expressing a protein, such vectors include chromosomal, non-chromosomal and synthetic DNA sequences. Examples of suitable vectors include derivatives of bacterial plasmids; phage DNA; yeast plasmids; vectors derived from combinations of plasmids and phage DNA and viral DNA. However, any other plasmid or vector may be used as long as it is replicable and viable in the host.

More particularly, the present invention also provides recombinant constructs comprising one or more of the nucleotide sequences as described above. The constructs comprise an expression vector, such as a plasmid or viral vector into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment the construct further comprises one or more regulatory sequences to direct messenger mRNA synthesis, including, for example a promoter operably linked to the sequence. Suitable promoters include: CMV, LTR, actin or SV40 promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector may contain an enhancer and a ribosome binding site for translation initiation and transcription terminator.

Large numbers of suitable vectors and promoters/enhancers, will be known to those of skill in the art, but any plasmid or vector, promoter/enhancer may be used as long as it is replicable and functional in the host.

Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts include mammalian expression vectors, insect expression vectors, yeast expression vectors, bacterial expression vectors and viral expression vectors and are described in Sambrook *et al*, Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor, NY. (1989). The vector may also include appropriate sequences for selection and/or amplification of expression. For this the vector will comprise one or more phenotypic selectable/amplifiable markers, such markers are also well known to those skilled in the art.

In a further embodiment, the present invention provides host cells capable of expressing a nucleotide sequence of the invention, the host cell can be, for example, a higher eukaryotic cell, such as mammalian cell or a lower eukaryotic cell, such as a yeast cell or a prokaryotic cell such as a bacterial cell. Suitable prokaryotic hosts for transformation include *E-coli*. Other examples include viral expression vectors, insect expression systems and yeast expression systems.

Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

The IKK4 protein is recovered and purified from recombinant cell cultures by methods known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, and ion or cation exchange chromatography, phosphocellulose chromatography and lecithin chromatography. Protein refolding steps may be used, as necessary, in completing configuration of the mature protein. Finally high performance liquid chromatography (HPLC) can be employed for final purification steps.

The present invention also provides antibodies specific for the IKK4 protein. The term antibody as used herein includes all immunoglobulins and fragments thereof which contain recognition sites for antigenic determinants of proteins of the present invention. The antibodies of the present invention may be polyclonal or preferably monoclonal, may be intact antibody molecules or fragments containing the active binding region of the antibody, e.g. Fab or (Fab)₂. The present invention also includes chimaeric, single chain and

humanised antibodies and fusions with non-immunoglobulin molecules. Various procedures known in the art may be used for the production of such antibodies and fragments.

5 The proteins, their variants especially fragments, derivatives, or analogues thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto. Antibodies generated against the IKK4 protein can be obtained by direct injection of the polypeptide into an animal, preferably a non-human. The antibody so obtained will then bind the protein itself. In this
10 manner, even a sequence encoding only a fragment of the protein can then be used to generate antibodies binding the whole native protein. Such antibodies can be used to locate the protein in tissue expressing that protein.

The antibodies of the present invention may also be of interest in purifying an
15 IKK4 protein and accordingly there is provided a method of purifying an IKK4 protein or any portion thereof which method comprises the use of an antibody of the present invention.

The present invention also provides methods of identifying modulators of the
20 IKK4 protein. Screens can be established for IKK4 enabling large numbers of compounds to be studied. High throughput screens may be based on ¹⁴C guanidine flux assays and fluorescence based assays as described in more detail below. Secondary screens may involve electrophysiological assays utilising patch clamp technology or two electrode voltage clamps to identify small
25 molecules, antibodies, peptides, proteins or other types of compounds that inhibit, block, or otherwise interact with the IKK4 protein. Tertiary screens may involve the study of the modulators in well characterised rat and mouse models of inflammation. These models of inflammation include, but are not restricted to inflammatory models (murine) atopic dermatitis models (murine and rat),
30 repeated-induced type dermatitis model (murine) and allergic asthma models (murine and guinea pig). For example, screens may be set up based on an in vitro phosphorylation system using bacterially expressed IKK4 proteins (see Example 3 and Figure 12). This system may be used to screen for modulators of the IKK4 kinase activity and then subsequently testing the effect of potential
35 modulators of IKK4 on gene expression, specifically the expression of IL-8 using

cell based assay systems. Finally the efficacy of these modulators in relation to inflammatory or allergic diseases may be tested on models of inflammation.

5 The invention therefore provides a method of assaying for a modulator comprising contacting a test compound with the IKK4 protein and detecting the activity or inactivity of the IKK4 protein. Preferably, the methods of identifying modulators or screening assays employed transformed host cells that express the IKK4 protein. Typically, such assays will detect changes in the activity of the IKK4 protein to the test compound, thus identifying modulators of the IKK4
10 protein.

Modulators of the present invention maybe an agonist, antagonist or mimetic of IKK4 activity.

15 In general, a test compound is added to the assay and its effect on IKK4 is determined or the test compound's ability to competitively bind to the IKK4 is assessed. Test compounds having the desired effect on the IKK4 protein are then selected.

20 IL-8 is involved in diseases involving inflammation and allergies. Specifically, asthma, atopic dermatitis, arthritis, rheumatoid arthritis, systemic lupus erythematosus, LPS - induced contact dermatitis, glomerulonephritis, gout and other inflammation-related diseases.

25 The invention therefore provides a modulator of a protein or a variant thereof as described above identifiable by a method described above for use in therapy. The invention further provides use of a modulator of an IKK4 protein optionally identifiable by a method described above for the manufacture of an anti-inflammatory medicament. Moreover the invention provides a method of
30 treatment which comprises administering to a patient an effective amount of a modulator of a protein as described above. More specifically, the invention provides a method of treating diseases related to inflammation, such as asthma, atopic dermatitis, arthritis, rheumatoid arthritis, systemic lupus erythematosus, LPS - induced contact dermatitis, glomerulonephritis and gout.
35

Complementary or anti-sense strands of the nucleotide sequences as herein above defined can be used in gene therapy. For example, the cDNA sequence of fragments thereof could be used in gene therapy strategies to down regulate the IKK4 protein. Anti-sense technology can be used to control gene expression
5 through triple-helix formation of anti-sense DNA or RNA, both of which methods are based on binding of a nucleotide sequence to DNA or RNA.

A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the product of the
10 sodium channel. The anti-sense RNA oligonucleotide hybridises to the messenger RNA *in vivo* and blocks translation of the messenger RNA into the IKK4 protein.

The regulatory regions controlling expression of the IKK4 protein could be used
15 in gene therapy to control expression of a therapeutic construct in cells expressing the IKK4 protein.

Figures**Brief Description of the Figures:****Figure 1**

5 Outside factors stimulating expression of NF- κ B as well as the effect of NF- κ B on various biological events.

Figure 2

10 Regulation of NF- κ B activity.

Figure 3

Schematic representation of IKK alpha, beta, IKK3 and IKK4
(KD = kinase domain; LZ = leucine zipper, HLH = helix-loop-helix). IKK3 is 25%
15 identical to IKK1 and 24% identical to IKK2 at the amino acid level. IKK α has a 52% identity to IKK β at the amino acid level.

Figure 4

Northern blot analysis:
20 The human tissue filter for the northern blot (gene hunter, TOYOBO) was probed with the IKK4 specific primers.

Figure 5

25 In vitro phosphorylation of I κ B proteins by IKK4.

Figure 6

IKK4 directly phosphorylates TRIP9.

The bacterially expressed GST-IKK4 were incubated with the bacterially expressed GST, GST-TRIP9, -TRIP9/AA and [γ -³²P] ATP for 30 min at 30°C.
30 Proteins were separated by SDS-PAGE, stained with Coomassie blue and analyzed by autoradiography

Figure 7

IKK4 controls an essential step in NF- κ B signalling pathway.

Example 1 Materials and methods**Cells and transfection**

5 Hela cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum. DNA transfection into cells was performed via DOSPER transfection according to the manufacture's instructions.

Vector construction

10 Two EST cDNA fragments (AA361478 and AA173512), similar to IKK3 were derived from one cDNA. The full lenght IKK4 cDNA was obtained by PCR from the human Jurkat cell line using Marathon cDNA Amplification kit (Clontech). The 5' half fragment (5'primer AP1 and 3' primer G198) and 3' half fragment (5' primer G197 and AP1) were amplified by PCR and digested with Nhe I. The resulting fragment was subcloned into pCR2.1-TOPO vector. To attach a Not I
15 site at the both ends of the cDNA, the cDNA was amplified by PCR with 5' primer G205 and 3' primer G213. The cDNA was sbcloned into a pCR2.1-TOPO vector.

G197: 5'-ACGAAGGGCGACGCTTAGTCTTAGAACC-3'

G198: 5'-GTGCGTCATAGCTTTTGTGGCATGGT-3'

20 G205: 5'-CCCCCGCGGCCGCCACCATGCAGAGCACTTCTAATCATCTG-3'

G213: 5'-CCCCCGCGGCCGCCCTAAAGACAGTCAACGTTGCGAAGGCC-3'

The cDNA fragment was digested with *NotI* and the fragment was subcloned into pGEX-4T (Pharmacia).

25 All PCR-derived sequences used in this study were confirmed by the Sanger method.

Example 2**Northern blot analysis**

30 **Expression of IKK4**

To test the expression of IKK4 in human tissues, we performed Nothern blot analysis. The IKK4 expression was detected in the Brain, Liver, Pancreas, Placenta and Lung, but not in the Heart (Fig. 6).

Example 3**In vitro phosphorylation**

Hela cells were transiently expressed with the double T7-tagged IKK4 (DT7-IKK4) expression vector. Thirty-six hours after transfection, cells were prepared
5 by lysis with TNE buffer (10 mM Tris-HCl, pH 7.8; 1% NP-40, 0.15 M NaCl; 1 mM EDTA; 10 mM NaF, 2mM Na₃VO₄, 10 mM PNPP and complete) and the IKK4 protein was immunoprecipitated with anti-T7 antibody. Purified DT7-IKK4 was used for in vitro kinase reactions with bacterially expressed GST, GST-IkB α (1-54), -IkB β (1-44), -IkB ϵ (140-244), -TRIP9 (1-44) and [γ -³²P] ATP. The
10 alanine-substitution mutants GST-IkB α (IkB α /AA), -IkB β (IkB β /AA), -TRIP9 (1-44, AA), -IkB ϵ (IkB ϵ /AA1 and IkB ϵ /AA2) were used as control proteins. Proteins were separated by SDS-PAGE, stained with Coomassie blue and analyzed by autoradiography.

15 In the case of direct phosphorylation of IkB by IKK4, the bacterially expressed GST-DT7-IKK4 was used as a kinase. 250 ng of purified kinase solution was used for in vitro kinase reactions with a 500 ng of bacterially expressed GST, GST-TRIP9 (1-44), -TRIP (1-44, AA) and [γ -³²P] ATP. Proteins were separated by SDS-PAGE, stained with Coomassie blue and analyzed by autoradiography.
20

Results:

To test whether IKK4 is able to phosphorylate IkBs, we transfected Hela cells with the double T7-tagged IKK4 expression vector. Thirty-six hours after transfection, IKK4 proteins were immunoprecipitated with anti-T7 antibody.
25 Purified IKK4 was used for in vitro kinase reactions, containing [γ -³²P] ATP and bacterially expressed GST, GST-IkB α (1-54 a.a.), -IkB β (1-44 a.a.), -IkB ϵ (140-244 a.a.), and -TRIP9 (1-44 a.a.).

The immunoprecipitates of the double T7-tagged IKK4 preferentially
30 phosphorylate GST-IkB β rather than GST-IkB α and IkB ϵ , while the immunoprecipitates did not phosphorylate GST in vitro (Fig. 7). Previously, it has been reported that residues Ser 32/Ser36 in IkB α and Ser19/Ser23 in IkB β become phosphorylated upon TNF- α or IL- α / β stimulation (Brockman et al., 1995; Brown et al., 1995; Traenchner et al., 1995; Whiteside et al., 1995;
35 DiDonato et al., 1996). To test whether these residues are phosphorylated by

IKK4, we mutated the residues in $\text{I}\kappa\text{B}\alpha$ to alanine. The corresponding residues of $\text{I}\kappa\text{B}\beta$ and $\text{I}\kappa\text{B}\epsilon$ were also mutated to alanine. The alanine-substitution mutants GST- $\text{I}\kappa\text{B}\alpha$ (1-54, AA), - $\text{I}\kappa\text{B}\beta$ (1-44, AA), were not phosphorylated at all (Fig. 7, lanes 3, 5). On the other hand, the alanine mutants of GST- $\text{I}\kappa\text{B}\epsilon$ (140-244, AA1 and AA2) were partially phosphorylated (Fig. 7, lanes 7 and 8).

These data suggest that IKK4 is involved in the $\text{I}\kappa\text{B}$ phosphorylation. However, it is still unclear whether IKK4 directly phosphorylates $\text{I}\kappa\text{B}$ s or requires some other molecules to modify the $\text{I}\kappa\text{B}$ s. We next examined whether IKK4 directly phosphorylates $\text{I}\kappa\text{B}$ s using a GST-pull down assay. We constructed GST-DT7-IKK4 and expressed the GST-IKK4 protein in *E. coli*. The affinity purified GST-IKK4 was used for the in vitro phosphorylation assay. The bacterially expressed GST, GST-TRIP9 or GST-TRIP9/AA were incubated with GST-IKK4 and [γ - ^{32}P] ATP. The proteins were separated by SDS-PAGE, stained with Coomassie blue and the gel was analyzed by autoradiography. Figure 8 shows that GST-IKK4 phosphorylates GST-TRIP9 but not GST and GST-TRIP9/AA. These results indicate that IKK4 directly phosphorylates serine 19 or 23 of $\text{I}\kappa\text{B}\beta$.

IKK4 regulates the NF- κB site of IL-8

Previously, we reported that IKK3 is able to control the IL-8 reporter gene via the NF- κB binding site. To test whether IKK4 regulates the NF- κB site of IL-8, DT7-IKK4 was transiently expressed in the human 293T cells with the IL-8 reporter gene. Transient expression of IKK4 activates the IL-8 reporter gene, while IKK4 is unable to activate the mutated reporter gene that contains a mutation at the NF- κB site of the IL-8 promoter (Fig. 9). These observations indicate that IKK4 is one of a critical kinases for the IL-8 gene regulation via the NF- κB site.

C L A I M S

1. The protein having the amino acid sequence in Seq. I.D No. 1, or a variant thereof.
- 5 2. An IKK4 kinase protein or variant thereof according to claim 1 for use in a method for screening for agents with anti-inflammatory activity.
- 10 3. A nucleotide sequence encoding the protein of claim 1 or a variant thereof, or a nucleotide sequence which is complementary thereto.
- 15 4. A nucleotide sequence encoding the protein of claim 1 as shown in Seq. I.D No. 2, or a variant thereof, or a nucleotide sequence which is complementary thereto.
- 20 5. The nucleotide sequence of either claim 3 or 4, which is a cDNA sequence.
6. A nucleotide sequence that hybridises to any part of a nucleotide strand referred to in either of claims 3 to 5.
- 25 7. An expression vector comprising a nucleotide sequence according to any one of claims 3 to 6, which is capable of expressing a IKK4 kinase protein or a variant thereof.
- 30 8. A stable cell line comprising a vector according to claim 7.
9. A cell line according to claim 8 which is a Hela cell line.
10. An antibody specific for a protein as claimed in claim 1.
- 35 11. A method for identification of a compound which exhibits IKK4 kinase modulating activity, comprising contacting a IKK4 kinase protein according to claims 1 or 2 with a test compound and detecting modulating activity or inactivity.

12. A compound which modulates the protein of claim 1, identifiable by a method according to claim 11.
- 5 13. A method of treatment or prophylaxis of a disorder which is responsive to modulation of IKK4 kinase activity in a mammal, which comprises administering to said mammal an effective amount of a compound identifiable by the method according to claim 11.
- 10 14. Use of a compound identifiable by the method according to claim 11 in a method of formulating a medicament for treatment or prophylaxis of a disorder which is responsive to the modulation of IKK4 kinase activity in a mammal.
- 15 15. A method of producing an IKK4 kinase protein comprising introducing into an appropriate cell line a suitable vector or vectors comprising a nucleotide sequence encoding for IKK4 or variants thereof, under conditions suitable for obtaining expression of the protein or variants.

1/12




FIG. 1

2/12




FIG. 2

3/12




FIG. 3

4/12




FIG. 4

5/12




FIG. 5

6/12




FIG. 6

7/12




FIG. 7

8/12

IKK1	MERPPGLRPGAGGPWEMRERLGTGGFCNVCLYQHRELDLKAIAKSCRLELSTKNRERWCH	60
IKK2	MSWSPSLTTQCCAWEMKERLGTGGFCNVIRWHNQETGEQIAIKQCRQELSPRNRERWCL	60
IKK3	-----MQSTANYLWHTDDLQGCATASVYKARNKKSCELVAVKVFNTTSYLRPREVQVR	54
IKK4	-----MQSTSNHLWLLSDILQGCATANVFRGRHKKTGDLFAIKVFNNISFLRPVDVQMR	54
IKK1	EIQIMKKLNHANVVKACDVPEELN-ILHDPVLLAMEYCSGGDLRKLKNKPENCCGLKES	119
IKK2	EIQIMRRLTHPNVVAARDVPEGMQLAPNDLP LLAMEYCSGGDLRKYLNQFENCCGLREG	120
IKK3	EFEVLRKLNHQNIVKLFAVEETGG----SRQKVLVMEYCSSGSLSVLESPENAFGLPED	110
IKK4	EFEVLKKNHKNIVKLFAIEEFTT----TRHKVLIMEFCPCGSLYTVLEEPSNAYGLPES	110
IKK1	QILSLSDIGSGIRYLHENKIHRLDKPENIVLQDVG-GKIHKIIDLGYAKDVDQGSCL	178
IKK2	AILTLLSDIASALRYLHENRIHRLDKPENIVLQQGE-QRLIHKIIDLGYAKELDQGSCL	179
IKK3	EFLVLRVCVAGMNLRENGIVHRDIKPGNIMRLVGEEGQSIYKLTDFCAARELDDDEKF	170
IKK4	EFLIVLRDVVCGMNLRENGIVHRDIKPCNIMRVIGEDGQSVYKLTDFCAARELEDDQF	170
IKK1	TSFVGTQLQYLAPELFE-----NKPYTATVDYWSFGTMVFECIAGYRPFLLHHLQP----	227
IKK2	TSFVGTQLQYLAPELLE-----QQKYTVTVDYWSFGTLAFECITGFRPFLPNWQP----	228
IKK3	VSVYGTTEEYLHPDMYERAVLRKPQKAFGVTVDLWSIGVTLYHAATGSLPFPFGCPRRN	230
IKK4	VSLYCTEEYLHPDMYERAVLRKDHQKKYGATVDLWSIGVTLYHAATGSLPFRPFEGPRRN	230
IKK1	--FTWHEKIKKKDPKCFACEEMSGEVRFSSHLPPQNSLCSLIVEPMENWLQMLNWDPO	285
IKK2	--VQWHSKVRQKSEVDIVVSEDNLGTVKFSSSLPPNPNLSVLAERLEKWLQMLMWHPR	286
IKK3	KEIMYRITTEKPAGALAGAQRRENCPLWSYTLPTCQLSLCLQSQLVPILANILEVE--	288
IKK4	KEVMYKITTKPSCAISGVQKAENGPIWDSCDMPVSCSLSRGLQVLLTPVLANILEAD--	288
IKK1	QRGGPVDLTLKQPRCFVLMDHILNLKIVHILNMTSAKISFLPPDESLSLSQSRIERET	345
IKK2	QRG--TDPTYGPNQCFKALDDILNLKLVHILNMVTGTIHTYPTVEDESLSLQKARIQQT	344
IKK3	QAK-----CWGFDQFFAETSDILQRVVHVFSLSQAVLHHIYHAHNTIAIFQEAHVHKQT	343
IKK4	QEK-----CWGFDQFFAETSDILHRMVIHVFSLQMTAHKIYHSYNTATIFHELVYKQT	343
IKK1	GINTGSQELLSETC-ISLDPRKPASQCVDG----VRGCDSYMVYLFDKSKTVYEGPFAS	400
IKK2	GIPEEDQELLQEAG-LALIPDKPATQCISDGKLNEGHTLMDLVFLDNSKITTYETQISP	403
IKK3	SVAPRHQEYLFEGHLCVLEPSV-SAQHIAHT-----TASSPLTLFSTA---IPKGLAF	392
IKK4	KISSNQELIYEGRRVLLEPGR-LAQHFPKT-----TEENPIFVVSRE---PLNTIGL	392
IKK1	RSLSDCVNYIVQDSKIQLPIQLRKVWAEAVHYVSGLKEDYSRLFQCQRAAMLSLLRYNA	460
IKK2	RPQPESVSCILQEPKRNLAFFQLRKVWGQVWHSIQTLKEDCNRLQQGQRAAMMNLNRNS	463
IKK3	RDPALDVPKFPKVDLQADYNTAKGVLGAGYQALRIARALLD----GQELMERGLHWVME	448
IKK4	IYEKISLPKVHPRYDLDCDASMAKAITGVVCIACRIATLLL----YQELMRKGIRWLE	448

FIG. 8

9/12

IKK1	NLTKMKNTLISASQQLKAKLEFFHKSQQLDLERYSEQMTYGISSEKMLKAWKEMEKAH	520
IKK2	CLSKMKNSMASMSQQLKAKLDFFKTSIQIDLEKYSEQTEFGITSDKLLAWREMEQAVEL	523
IKK3	VLQATCRRTLEVARTSLYLSSSLGTERFSSVACTPEIQELKAAAELRSRLTLAEVLSR	508
IKK4	LKDDYNETVHKKTEVVITLDFCIRNIEKTVKVYEKLMKINLEAAELC-EISDIHTKLLR	507
IKK1	YAEVGVIGYLEDQIMSLHAEIMEL-----QKSPYG-RRQGDLMESLEQRAIDLYKQ	570
IKK2	CGRENEVKLLVERMMALQTDIVDL-----QRSPMG-RKQCGTLDDEEQARELYRR	573
IKK3	CSQN--ITETQESLSSLNRELVKS-----RDQVHE-DRSIQQIQCCLDKMNFYKQ	556
IKK4	LSSS--QGTIETSLQDIDSRSLSPGCSLADAWAHQEGTHPKDRNVEKLQVLLNCMTIYYQ	565
IKK1	LKHRPSD-HSYSDSTEMVKIIVHTVQSQDRVLKELFGHLSKLLGCKQKNDLLPKVEVAL	629
IKK2	LREKPRDQRTEGDSQEMVRLLQAIQSFEKKVRVIYTQLSKTVVCKQKALELLPKVEEVV	633
IKK3	FKKSRMR-PGLGYNEEQ----IHKLDKVNFSHLAKRLLQVFQEECVQKYQASLVTHGKRM	611
IKK4	FKKDKAE-RRLAYNEEQ----IHKFDKQKLYYHATKAMTHFTDECVKKYEAFLNKSEEWI	620
IKK1	SNIKEADNTVMFMQCKRQKEIWHLLKIACQSSARSLVGSSELEGAVTPQTSAWLPPTSAE	689
IKK2	SLMNEDEKTVVRLQEKRQKELWNLLKIACSK--VRGPVSGSPD---SMNASRLSQPCQLM	688
IKK3	RVVHETRNHLRLVGCSVAACNTEAQGVQESLSKLEELSHQLLQDRAKGAQASPPPIAPY	671
IKK4	RKMLHLRKQLLSLTNQCFDIEEEVSKYQEYTNELQETLPQKMFTASS-GIKHTMTPIYPS	679
IKK1	HDHSLSCVVTPOGETSAQMIEENLNLCLGHLSTIHEANEEQGNMMLNDWSWLT-----	745
IKK2	SQPSTAQNSLPEPAKKSEELVAEHNLCITLLENAIQDQTVREQDQSFTALDWSWLQTEEEE	748
IKK3	PSPTRKDLLH-----MQELCEGMKLLASDLLDNRR--IIRLNRVPAPPDV-----	716
IKK4	-SNTLVEMTLG-----MKKLKEEMEGVVKELAENNH--ILERFCSLTMDGGLRNVDCI--	729
IKK1	-----	
IKK2	HSCLEQAS	756
IKK3	-----	
IKK4	-----	

Predicted amino acid sequence of IKK4.

The potential kinase domain (KD) and helix-loop-helix (HLH) are boxed. The potential leucine zipper are underlined. Asterisks and dots indicate identical and similar amino acids, respectively. Numbers in the right indicate position of the amino acids.

FIG. 9

10/12

ikk4.seq Length: 3372

1 GTTGTA AAC GACGGCCAGT GAATTGTAAT ACGACTCACT ATAGGGCGAA
51 TTGGGCCCCTC TAGATGCATG CTCGAGCGGC CGCCAGTGTG ATGGATATCT
101 GCAGAATTCG CCCTTCCATC CTAATACGAC TCACTATAGG GCTCGAGCGG
151 CCGCCCGGGC AGGTCCAGGG CTGCGAAGC CGGAAGTGTG CTGAGTCTCG
201 AGGAGGCCGC GGGAGCCCGC CGGCGGTGGC GCGGCGGAGA CCCGGCTGGT
251 ATAACAAGAG GATTGCCTGA TCCAGCCAAG ATGCAGAGCA CTTCTAATCA
301 TCTGTGGCTT TTATCTGATA TTTAGGCCA AGCAGCTACT GCAAATGTCT
351 TTCGTGGAAG ACATAAGAAA ACTGGTGATT TATTTGCTAT CAAAGTATTT
401 AATAACATAA GCTTCCTTCG TCCAGTGCAT GTTCAAATGA GAGAATTTGA
451 AGTGTTGAAA AAAC TCAATC AAAAAATAT TGTCAAATTA TTTGCTATTG
501 AAGAGGAGAC AACACAAGA CATAAAGTAC TTATTATGGA ATTTTGTCCA
551 TGTGGGAGTT TATACACTGT TTTAGAAGAA CCTTCTAATG CCTATGGACT
601 ACCAGAATCT GAATTCCTAA TTGTTTTGCG AGATGTGGTG GGTGGAATGA
651 ATCATCTACG AGAGAATGGT ATAGTGCACC GTGATATCAA GCCAGGAAAT
701 ATCATGCGTG TTATAGGGGA AGATGGACAG TCTGTGTACA AACTCACAGA
751 TTTTGGTGCA GCTAGAGAAT TAGAAGATGA TGAGCAGTTT GTTCTCTGT
801 ATGGCACAGA AGAATATTTG CACCCTGATA TGTATGAGAG AGCAGTCCTA
851 AGAAAAGATC ATCAGAAGAA ATATGGAGCA ACAGTTGATC TTTGGACCAT
901 TGGGGTAACA TTTTACCATG CAGCTACTGG ATCACTGCCA TTTAGACCCT
951 TTGAAGGGCC TCGTAGGAAT AAAGAAGTGA TGTATAAAAT AATTACAGGA
1001 AAGCCTTCTG GTGCAATATC TGGAGTACAG AAAGCAGAAA ATGGACCAAT
1051 TGACTGGAGT GGAGACATGC CTGTTTCTTG CAGTCTTTCT CGGGGTCTTC

FIG. 10

11/12

1101 AGGTTCTACT TACCCCTGTT CTTGCAAACA TCCTTGAAGC AGATCAGGAA
1151 AAGTGTTGGG GTTTTGACCA GTTTTTTGCA GAAACTAGTG ATATACTTCA
1201 CCGAATGGTA ATTCATGTTT TTTGCTACA ACAAATGACA GCTCATAAGA
1251 TTTATATACA TAGCTATAAT ACTGCTACTA TATTTTCATGA ACTGGTATAT
1301 AAACAAACCA AAATTATTTT TTCAAATCAA GAACTTATCT ACGAAGGGCG
1351 ACGCTTAGTC TTAGAACCTG GAAGGCTGGC ACAACATTTT CCTAAACTA
1401 CTGAGGAAAA CCCTATATTT GTAGTAAGCC GGGAACCTCT GAATACCATA
1451 GGATTAATAT ATGAAAAAT TTCCCTCCCT AAAGTACATC CACGTTATGA
1501 TTTAGACGGG GATGCTAGCA TGGCTAAGGC AATAACAGGG GTTGTGTGTT
1551 ATGCCTGCAG AATTGCCAGT ACCTTACTGC TTTATCAGGA ATTAATGCCA
1601 AAGGGGATAC GATGGCTGAT TGAATTAATT AAAGATGATT ACAATGAAAC
1651 TGTTCACAAA AAGACAGAAG TTGTGATCAC ATTGGATTTT TGTATCAGAA
1701 ACATTGAAAA AACTGTGAAA GTATATGAAA AGTTGATGAA GATCAACCTG
1751 GAAGCGGCAG AGTTAGGTGA AATTCAGAC ATACACACCA AATTGTTGAG
1801 ACTTTCCAGT TCTCAGGCAA CAATAGAAAC CAGTCTTCAG GATATCGACA
1851 GCAGATTATC TCCAGGTGGA TCACTGGCAG ACGCATGGGC ACATCAAGAA
1901 GGCATCATC CGAAAGACAG AAATGTAGAA AACTACAAG TCCTGTAAAA
1951 TTGCATGACA GAGATTTACT ATCAGTTCAA AAAAGACAAA GCAGAACGTA
2001 GATTAGCTTA TAATGAAGAA CAAATCCACA AATTTGATAA GCAAAAAGTG
2051 TATTACCATG CCACAAAAGC TATGACGCAC TTTACAGATG AATGTGTAA
2101 AAAGTATGAG GCATTTTGA ATAAGTCAGA ACAATGGATA AGAAAGATGC
2151 TTCATCTTAG GAAACAGTTA TTATCGCTCA CTAATCAGTG TTTTGATATT
2201 GAAGAAGAAG TATCAAAATA TCAAGAATAT ACTAATGAGT TACAAGAAAC

FIG. 11

12/12

2251 TCTGCCTCAG AAAATGTTTA CAGCTTCCAG TGGAATCAAA CATACCATGA
2301 CCCC AATTTA TCCAAGTTCT AACACATTAG TAGAAATGAC TCTTGGTATG
2351 AAGAAATTAA AGGAAGAGAT GGAAGGGCTG GTTAAAGAAC TTGCTGAAAA
2401 TAACCACATT TTAGAAAGGT TTGGCTCTTT AACCATGGAT GGTGGCCTTC
2451 GCAACGTTGA CTGTCTTTAG CTTTCTAATA GAAGTTTAAG AAAAGTTTCC
2501 GTTTGCACAA GAAAATAACG CTTGGGCATT AAATGAATGC CTTTATAGAT
2551 AGTCACTTGT TTCTACAATT CAGTATTTGA TGTGGTCGTG TAAATATGTA
2601 CAATATTGTA AATACATAAA AAATATACAA ATTTTGGCT GCTGTGAAGA
2651 TGTAATTTTA TCTTTTAACA TTTATAATTA TATGAGGAAA TTTGACCTCA
2701 GTGATCACGA GAAGAAAGCC ATGACCGACC AATATGTTGA CATACTGATC
2751 CTCTACTCTG AGTGGGGCTA AATAAGTTAT TTTCTCTGAC CGCCTACTGG
2801 AAATATTTTT AAGTGGAACC AAAATAGGCA TCCTTACAAA TCAGGAAGAC
2851 TGACTTGACA CGTTTGTAAG TGGTAGAACG GTGGCTACTG TGAGTGGGGA
2901 GCAGAACCGC ACCACTGTTA TACTGGGATA ACAATTTTTT TGAGAAGGAT
2951 AAAGTGGCAT TATTTTATTT TACAAGGTGC CCAGATCCCA GTTATCCTTG
3001 TATCCATGTA ATTT CAGATG AATTATTAAG CAAACATTTT AAAGTGAATT
3051 CATTATTAAA AACTATTCAT TTTTTCCTT TGGCCATAAA TGTGTAATTG
3101 TCATTAAAAAT TCTAAGGTCA TTTCAACTGT TTTAAGCTGT ATTTCTTTAA
3151 TTCTGCTTAC TATTT CATGG AAAAAAATAA ATTTCTCAAT TTTAAAAAAA
3201 AAAAAAAAAA AAAAAAAGC GTTCTAGAAT TCAGCGGCCG CTGAATTCTA
3251 GACCTGCCCC GCGGGCCGCT CGAGCCCTAT AGTGAGTCGT ATTAGGATGG
3301 AAGGGCGAAT TCCAGCACAC TGGCGGCCGT TACTAGTGA TCCGAGCTCG
3351 GTACCAAGCT TGGCGTAATC AG

FIG. 12

```

                                     ##
                                     #
## ####      ###   ###   #####   #####   #####   #   ##   #####   ##   ###   #####
##          #     #   #       #   #       #   ##   #   #       #   ##   #   #       #
#           #   #   #   #####   #####   #       #   #       #   #####   #####
#           #   #   #   #       #   #       #   #       #   #       #   #       #
#           #   #   #   #       #   #       #   #       #   #       #   #       #
#####      #   #   #####   #####   #####   #####   #####   #####   #####

```

Job : 242
Date: 7/5/2006
Time: 9:06:39 AM

SEQUENCE LISTING

<110> GeneSense Technologies Inc. et al.

<120> Antisense Oligonucleotides Directed To
Ribonucleotide Reductase R2 and Uses Thereof in Combination
Therapies for the Treatment of Cancer

<130> 683-134pct

<140> n/a

<141> 2005-01-12

<150> US60/535,496

<151> 2004-01-12

<150> US60/602,817

<151> 2004-08-18

<160> 105

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense oligonucleotide complementary to human
ribonucleotide reductase R2 mRNA

<400> 1

ggctaaatcg ctccaccaag

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Control antisense oligonucleotide

<400> 2

ggctaaactc gtccaccaag

20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Control oligonucleotide

<400> 3

acgcactcag ctagtgacac

20

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

seq.txt

<220>
 <223> AS-II-6-20 antisense oligonucleotide complementary
 to human ribonucleotide reductase R2 mRNA

<400> 4
 acccttccca ttggctgctg 20

<210> 5
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-13-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 5
 gcctccgacc cttcccattg 20

<210> 6
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-14-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 6
 tgcctccgac ccttcccatt 20

<210> 7
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-16-18 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 7
 tgcctccgac ccttccca 18

<210> 8
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Partially Phosphorothioated AS-II-75-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 8
 cgcgcgctcc cggcccttcc 20

<210> 9
 <211> 20
 <212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-75-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 9

cgcgcgctcc cggcccttcc

20

<210> 10

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-79-14 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 10

cgcgctcccg gccc

14

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-109-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 11

cccctcactc cagcagcctt

20

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-110-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 12

accctcact ccagcagcct

20

<210> 13

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-114-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 13

ggcgaccct cactccagca

20

<210> 14

<211> 12
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-127-12 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 14
 gcacgggcga cc 12

<210> 15
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-130-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 15
 tgggacaggg tgcacgggcg 20

<210> 16
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-134-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 16
 gacggctggg acaggggtgca 20

<210> 17
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-151-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 17
 gagcagccag gacaggacgg 20

<210> 18
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-163-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 18
 gcgaagcaga gcgagcagcc 20

seq.txt

<210> 19
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-166-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 19
 gcagcgaagc agagcgagca 20

<210> 20
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-185-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 20
 gggagagcat agtggaggcg 20

<210> 21
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-189-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 21
 cggagggaga gcatagtgga 20

<210> 22
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-201-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 22
 gcgagcggga cacggaggga 20

<210> 23
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-217-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 23
 cgggtccgtg atgggcgcga 20
 <210> 24
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> AS-II-225-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA
 <400> 24
 agctgctgcg ggtccgtgat 20
 <210> 25
 <211> 14
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> AS-II-253-14 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA
 <400> 25
 ccccttcagc ggcg 14
 <210> 26
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> AS-II-280-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA
 <400> 26
 cggcggcgtg ttctccttgt 20
 <210> 27
 <211> 12
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> AS-II-288-12 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA
 <400> 27
 cggcggcgtg tt 12
 <210> 28
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> AS-II-323-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2

mRNA

<400> 28
tcctcgcggt cttgctggcc 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-344-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 29
ccgtgggctc ctggaagatc 20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-362-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 30
ctgcttagt tttcggctcc 20

<210> 31
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-391-17 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 31
cggctcatcc tccacgc 17

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-404-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 32
ggttttctct cagcagcggc 20

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

seq.txt

<223> AS-II-412-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 33
gcggcggggg ttttctctca 20

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-414-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 34
aagcggcggg ggttttctct 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-425-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 35
ggaagatgac aaagcggcgg 20

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-439-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 36
atggtactcg atggggaaga 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-472-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 37
agcctctgcc ttcttataca 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

seq.txt

<220>
 <223> AS-II-494-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 38
 cctcctcggc ggtccaaaag 20

<210> 39
 <211> 16
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-496-16 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 39
 tcctcggcgg tccaaa 16

<210> 40
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-549-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 40
 tatctctcct cgggtttcag 20

<210> 41
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-579-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 41
 gcaaagaaag ccagaacatg 20

<210> 42
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-619-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 42
 tcgctccacc aagttttcat 20

<210> 43
 <211> 20

<212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-634-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 43
 aacttcttgg ctaaatacgct 20

<210> 44
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-667-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 44
 gaagccatag aaacagcggg 20

<210> 45
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-784-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 45
 gacacaaggc atcgtttcaa 20

<210> 46
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-798-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 46
 tctgccttct tcttgacaca 20

<210> 47
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-816-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 47
 atccagcgca aggcccagtc 20

<210> 48
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-861-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 48
 gcaaaggcta caacacgttc 20

<210> 49
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-890-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 49
 aaccggaaaa gaaaatgcct 20

<210> 50
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-909-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 50
 ggcatcagtc ctcgtttcct 20

<210> 51
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-933-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 51
 ggcatcagtc ctcgtttcct 20

<210> 52
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-981-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 52

	seq.txt	
tgtaaaccct catctctgct		20
<210> 53		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1001-20 antisense oligonucleotides complementary to human ribonucleotide reductase R2 mRNA		
<400> 53		
tcaggcaagc aaaatcacag		20
<210> 54		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1006-20 antisense oligonucleotides complementary to human ribonucleotide reductase R2 mRNA		
<400> 54		
gaacatcagg caagcaaaat		20
<210> 55		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1023-20 antisense oligonucleotides complementary to human ribonucleotide reductase R2 mRNA		
<400> 55		
ttgtgtacca ggtgtttgaa		20
<210> 56		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1040-20 antisense oligonucleotides complementary to human ribonucleotide reductase R2 mRNA		
<400> 56		
ctctctcctc cgatggtttg		20
<210> 57		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1048-20 antisense oligonucleotides complementary to human ribonucleotide reductase R2 mRNA		

seq.txt

<400> 57
ttctcttact ctctcctccg 20

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1144-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 58
gtattgcttc attagagtgc 20

<210> 59
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1182-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 59
cccagttcca gcataagtct 20

<210> 60
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1197-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 60
aaaaccttgc taaaacccag 20

<210> 61
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1217-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 61
caaatgggtt ctctactctg 20

<210> 62
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1224-20 antisense oligonucleotides
Page 13

seq.txt

complementary to human ribonucleotide reductase R2
mRNA

<400> 62
ataaagtcaa atgggttctc 20

<210> 63
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1254-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 63
ttagtctttc cttccagtga 20

<210> 64
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1278-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 64
tcgcctactc tcttctcaaa 20

<210> 65
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1288-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 65
cctctgatac tcgcctactc 20

<210> 66
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1302-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 66
gacatcactc ccatacctctg 20

<210> 67
<211> 20
<212> DNA
<213> Artificial Sequence

seq.txt

<220>
 <223> AS-II-1335-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 67
 gcatccaagg taaaagaatt 20

<210> 68
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-1338-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 68
 tcagcatcca aggtaaaaga 20

<210> 69
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-1342-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 69
 gaagtcagca tccaaggtaa 20

<210> 70
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-1345-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 70
 ttagaagtca gcatccaagg 20

<210> 71
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-1362-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 71
 gcacatcttc agttcattta 20

<210> 72
 <211> 20
 <212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1364-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 72

gggcacatct tcagttcatt

20

<210> 73

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1381-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 73

aaaaatcagc caagtaaggg

20

<210> 74

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1390-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 74

atggaaaaaa aaaatcagcc

20

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1438-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 75

ttcatggtgt ggctagttgg

20

<210> 76

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1499-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 76

aggactgggtt gtgaggtagc

20

<210> 77

<211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1517-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 77
 ccagcactat aaacagacag 20

 <210> 78
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1538-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 78
 ttctggcaaa aggtgatact 20

 <210> 79
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1560-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 79
 gtaagtcaca gccagccagg 20

 <210> 80
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1581-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 80
 actgccattg tcactgctat 20

 <210> 81
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1659-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 81
 tggctgtgct ggttaaagga 20

seq.txt

<210> 82
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1666-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 82
 ttttaactgg ctgtgctggt 20

 <210> 83
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1700-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 83
 attaaaatct gcgttgaagc 20

 <210> 84
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1768-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 84
 tatcgccgcc gtgagtacaa 20

 <210> 85
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1773-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 85
 gctattatcg ccgccgtgag 20

 <210> 86
 <211> 12
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1775-12 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 86
 atcgccgccg tg 12

 <210> 87
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1790-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 87
 gaaaccaa ataatcaagct 20

 <210> 88
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1819-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 88
 ttagtggtca ggagaatgta 20

 <210> 89
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1976-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 89
 tggaccaac tgactaatat 20

 <210> 90
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-1989-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

 <400> 90
 cctgtcttct atctggcacc 20

 <210> 91
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> AS-II-2009-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

mRNA

<400> 91
gccacaggat aaaaacacaa 20

<210> 92
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2026-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 92
cccaggacac tacacaagcc 20

<210> 93
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2044-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 93
tcagaggggg cagagaatcc 20

<210> 94
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2067-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 94
tcctttatcc cacaacactc 20

<210> 95
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2083-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 95
ccttgccctg agagattcct 20

<210> 96
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Partially Phosphorothioated AS-II-2083-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 96
ccttgccctg agagattcct 20

<210> 97
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2128-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 97
ggcccagatc acccctaaat 20

<210> 98
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2151-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 98
aaacggcttc tcacacatat 20

<210> 99
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2164-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 99
gagaaataaa atgaaacggc 20

<210> 100
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2182-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 100
cgttgaggaa aatacagtga 20

<210> 101
<211> 20
<212> DNA
<213> Artificial Sequence

seq.txt

<220>
 <223> AS-II-2229A-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 101
 gctcccat atgaaaactc 20

<210> 102
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AS-II-2372-20 antisense oligonucleotides
 complementary to human ribonucleotide reductase R2
 mRNA

<400> 102
 cacacaacct acttacacca 20

<210> 103
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Antisense oligonucleotides complementary to human
 ribonucleotide reductase R2 mRNA

<400> 103
 tcctggaaga tcctcctcgc 20

<210> 104
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Antisense oligonucleotides complementary to human
 ribonucleotide reductase R2 mRNA

<400> 104
 tcccatatat gagaaaactc 20

<210> 105
 <211> 2500
 <212> DNA
 <213> Homo sapiens

<220>
 <221> mRNA
 <222> (1)...(2500)
 <223> ribonucleotide reductase R2 mRNA

<400> 105
 cccaggcgca gccaatggga agggtcggag gcatggcaca gccaatggga agggccgggg 60
 caccaaagcc aatgggaagg gccgggagcg cgcggcgcgg gagatttaaa ggctgctgga 120
 gtgaggggtc gcccggtgcac cctgtcccag ccgtcctgtc ctggctgctc gctctgcttc 180
 gctgcgcctc cactatgctc tccctccgtg tcccgcctgc gccatcacg gacccgcagc 240
 agctgcagct ctgcgcgctg aaggggctca gcttggtcga caaggagaac acgccgccgg 300
 ccctgagcgg gacccgcgtc ctggccagca agaccgcgag gaggatcttc caggagccca 360

seq.txt

cggagccgaa	aactaaagca	gctgcccccg	gcgtggagga	tgagccgctg	ctgagagaaa	420
acccccgccg	ctttgtcatc	ttccccatcg	agtacatga	tatctggcag	atgtataaga	480
aggcagaggc	ttccttttgg	accgccgagg	agggtgacct	ctccaaggac	attcagcact	540
gggaatccct	gaaacccgag	gagagatatt	ttatatccca	tgttctggct	ttctttgcag	600
caagcgatgg	catagtaaat	gaaaacttgg	tggagcgatt	tagccaagaa	gttcagatta	660
cagaagcccg	ctgtttctat	ggcttccaaa	ttgccatgga	aaacatacat	tctgaaatgt	720
atagtcttct	tattgacact	tacataaaaag	atcccaaaga	aagggaattt	ctcttcaatg	780
ccattgaaac	gatgccttgt	gtcaagaaga	aggcagactg	ggccttgccg	tggattgggg	840
acaaagaggc	tacctatggt	gaacgtgttg	tagcctttgc	tgcaagtggaa	ggcattttct	900
tttccgggtc	ttttgcgtcg	atattctggc	tcaagaaacg	aggactgatg	cctggcctca	960
catttttctaa	tgaacttatt	agcagagatg	agggtttaca	ctgtgatttt	gcttgcctga	1020
tgttcaaaca	cctggtacac	aaacctatcg	aggagagagt	aagagaaaata	attatcaatg	1080
ctgttcggat	agaacaggag	ttcctcactg	aggccttgcc	tgtgaagctc	attgggatga	1140
attgcactct	aatgaagcaa	tacattgagt	ttgtggcaga	cagacttatg	ctggaactgg	1200
gttttagcaa	ggttttcaga	gtagagaacc	catttgactt	tatggagaat	atttcactgg	1260
aaggaaagac	taacttcttt	gagaagagag	taggcgagta	tcagaggatg	ggagtgatgt	1320
caagtccaac	agagaattct	tttaccttgg	atgctgactt	ctaaatgaac	tgaagatgtg	1380
cccttacttg	gctgattttt	tttttccatc	tcataagaaa	aatcagctga	agtgttacca	1440
actagccaca	ccatgaattg	tccgtaatgt	tcattaacag	catctttaaa	actgtgtagc	1500
tacctcacaa	ccagtcctgt	ctgtttatag	tgctggtagt	atcacctttt	gccagaaggc	1560
ctggctggct	gtgacttacc	atagcagtga	caatggcagt	cttggcttta	aagtgagggg	1620
tgacccttta	gtgagcttag	cacagcgga	ttaaacagtc	ctttaaccag	cacagccagt	1680
taaaagatgc	agcctcactg	cttcaacgca	gattttaatg	tttacttaaa	tataaacctg	1740
gcactttaca	aacaaataaa	cattgttttg	tactcacggc	ggcgataata	gcttgattta	1800
tttggtttct	acaccaaata	cattctcctg	accactaatg	ggagccaatt	cacaattcac	1860
taagtgacta	aagtaagtta	aacttggtga	gactaagcat	gtaattttta	agttttattt	1920
taatgaatta	aaatatitgt	taaccaactt	taaagtcagt	cctgtgtata	cctagatatt	1980
agtcagttgg	tgccagatag	aagacagggt	gtgtttttat	cctgtggcct	gtgtagtgtc	2040
ctgggattct	ctgccccctc	tgagtagagt	gttgtgggat	aaagggaatct	ctcagggcaa	2100
ggagcttctt	aagttaaatc	actagaaatt	taggggtgat	ctgggccttc	atatgtgtga	2160
gaagccggtt	catttttattt	ctcactgtat	tttctcaac	gtctggttga	tgagaaaaaa	2220
ttcttgaaga	gttttcatat	gtgggagcta	aggtagtatt	gtaaaatttc	aagtcatcct	2280
taaacaaaat	gatccaccta	agatcttgcc	cctgttaagt	ggtgaaatca	actagagggtg	2340
gttctacaa	gttgttcatt	ctagttttgt	ttggtgtaag	taggttgtgt	gagttaattc	2400
atttatattt	actatgtctg	ttaaatacaga	aattttttat	tatctatggt	cttctagatt	2460
ttacctgtag	ttcataaaaa	aaaaaaaaaa	aaaaaaaaaa			2500